Nectar Lifesciences Limited (BOM:532649)

Market Cap	2.22B -63.5%
Revenue (ttm)	n/a
Net Income	-2.93B
EPS	-13.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,447
Open	11.41
Previous Close	11.50
Day's Range	11.36 - 11.63
52-Week Range	9.20 - 23.80
Beta	n/a
Analysts	Strong Buy
Price Target	42.00 (+265.22%)
Earnings Date	May 30, 2026

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufa...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,786
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532649

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 20, 2026

Data Sources Report a data error